Modern strategy of drug therapy and metastatic castrate-resistant prostate cancer

Prostate cancer is one of the most common malignant tumors in men. In some patients recurrent or metastatic forms of the disease can be detected at diagnosis or after the initial therapy, which may require the use of systemic treatment, including chemotherapy. The purpose of this review is to summarize the current standards of care, with hormone-sensitive and castrate-resistant forms of prostate cancer, in the light of emerging new medical treatments. Abiraterone acetate and enzalutamid were first evaluated in patients as second-line drugs after progression on docetaxel. Furthermore, indications for chemotherapy can be expanded to a hormone-naive patients with metastatic prostate cancer. However, there is some uncertainty regarding the optimal drug strategy. Long-term results of these studies will help to further define the role of chemotherapy in prostate cancer, and help to clarify the general strategy for the treatment of patients with metastatic prostate cancer.